ホームHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
前日の終値
€25.85
日次変動幅
€25.67 - €25.67
年間変動幅
€19.52 - €36.69
時価総額
35.84億 USD
株価収益率
-
配当利回り
-
優先市場
NASDAQ
ニュース トピック
財務情報
損益計算書
収益
純利益
(USD) | 2024年3月info | 前年比変化率 |
---|---|---|
収益 | — | — |
営業費用 | 1.26億 | 28.63% |
純利益 | -1.25億 | -357.42% |
純利益率 | — | — |
1 株当たりの収益 | -1.02 | -326.67% |
EBITDA | -1.22億 | -339.34% |
実効税率 | — | — |
貸借対照表
総資産
負債総額
(USD) | 2024年3月info | 前年比変化率 |
---|---|---|
現金および短期投資 | 5.21億 | 8.30% |
総資産 | 9.55億 | 7.16% |
負債総額 | 4.60億 | 7.87% |
純資産 | 4.95億 | — |
発行済み株式 | 1.24億 | — |
帳簿価格 | 6.63 | — |
総資産利益率 | -39.90% | — |
資本利益率 | -43.18% | — |
キャッシュ フロー
現金の純増減額
(USD) | 2024年3月info | 前年比変化率 |
---|---|---|
純利益 | -1.25億 | -357.42% |
営業キャッシュ フロー | -9237.70万 | -191.68% |
投資キャッシュ フロー | -2.69億 | -645.70% |
財務キャッシュ フロー | 4.31億 | 82,741.73% |
現金の純増減額 | 6948.90万 | 203.27% |
フリー キャッシュ フロー | -9182.49万 | -262.49% |
概要
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
設立
2004/01/01
本社所在地
ウェブサイト
従業員数
525